BERLIN and SEATTLE, Nov. 4, 2008 (GLOBE NEWSWIRE) -- Epigenomics AG (Frankfurt Prime Standard: ECX), a cancer molecular diagnostics company developing tests based on DNA methylation, today reported financial results for the third quarter and for the first nine months of 2008, ended September 30, 2008, and provided a corporate update.
